Aliases & Classifications for Swine Influenza

MalaCards integrated aliases for Swine Influenza:

Name: Swine Influenza 12 52 3 14 69
Influenza Due to Influenza a Virus Subtype H1n1 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050211

Summaries for Swine Influenza

CDC : 3 Swine influenza is a respiratory disease of pigs caused by type A influenza viruses that regularly cause outbreaks of influenza in pigs. Influenza viruses that commonly circulate in swine are called “swine influenza viruses” or “swine flu viruses.” Like human influenza viruses, there are different subtypes and strains of swine influenza viruses. The main swine influenza viruses circulating in U.S. pigs in recent years have been, swine triple reassortant (tr) H1N1 influenza virus, trH3N2 virus, and trH1N2 virus.

MalaCards based summary : Swine Influenza, also known as influenza due to influenza a virus subtype h1n1, is related to influenza and pneumonia, and has symptoms including coughing, fever and pruritus. An important gene associated with Swine Influenza is GP2 (Glycoprotein 2). The drugs Vitamin A and Vitamin C have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and heart.

Disease Ontology : 12 An influenza that results_in infection located in respiratory tract of pigs and humans, has material basis in Influenza C virus, or has material basis in Influenza A virus subtypes (H1N1, H1N2, H3N1, H3N2, and H2N3), which are transmitted_by direct contact with infected pigs. The infection in humans has symptom fever, has symptom lethargy, has symptom lack of appetite, has symptom coughing, has symptom runny nose, has symptom sore throat, has symptom nausea, has symptom vomiting, and has symptom diarrhea.

Wikipedia : 72 Swine influenza is an infection caused by any one of several types of swine influenza viruses. Swine... more...

Related Diseases for Swine Influenza

Diseases related to Swine Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 influenza 11.0
2 pneumonia 10.3
3 infant botulism 10.0 GP2 HAS1
4 avian influenza 10.0
5 legionnaires' disease 9.8
6 respiratory failure 9.8
7 lupus erythematosus 9.8
8 pleuropneumonia 9.8
9 narcolepsy 9.8
10 cerebritis 9.8
11 lymphopenia 9.8
12 systemic lupus erythematosus 9.8
13 legionnaire disease 9.8
14 appendicitis 9.8
15 orofaciodigital syndrome 9.7 HAS1 NEU1 TNF
16 colon adenocarcinoma 9.7 TGM3 TNF
17 telogen effluvium 9.7 NEU1 POLR1A
18 infective endocarditis 9.6
19 chronic fatigue syndrome 9.6
20 endocarditis 9.6
21 neuropathy 9.6
22 smallpox 9.6
23 vaccinia 9.6
24 parainfluenza virus type 3 9.6
25 virus associated hemophagocytic syndrome 9.6
26 plague 9.6
27 mouth disease 9.6
28 rheumatoid arthritis 9.6
29 myocardial infarction 9.6
30 acute disseminated encephalomyelitis 9.6
31 myocarditis 9.6
32 arthritis 9.6
33 thrombocytopenia 9.6
34 polycystic echinococcosis 6.5 FGD1 GP2 HAS1 NEU1 POLR1A SLC8B1

Graphical network of the top 20 diseases related to Swine Influenza:



Diseases related to Swine Influenza

Symptoms & Phenotypes for Swine Influenza

UMLS symptoms related to Swine Influenza:


coughing, fever, pruritus, snoring

Drugs & Therapeutics for Swine Influenza

Drugs for Swine Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
2
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
3
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
4 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
5 Antioxidants Phase 4
6 Antipyretics Phase 4
7 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
8 Micronutrients Phase 4
9 Protective Agents Phase 4
10 Retinol palmitate Phase 4
11 Trace Elements Phase 4
12 Vitamins Phase 4
13 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
14 Antibodies Phase 4,Phase 2,Phase 1
15 Immunoglobulins Phase 4,Phase 2,Phase 1
16 MF59 oil emulsion Phase 4,Phase 2,Phase 3,Phase 1
17 Immunosuppressive Agents Phase 4
18 Hemagglutinins Phase 4,Phase 2,Phase 1
19 retinol Nutraceutical Phase 4
20
Oseltamivir Approved Phase 3,Phase 2 204255-11-8, 196618-13-0 65028
21
Zanamivir Approved, Investigational Phase 3,Phase 2 139110-80-8 60855
22
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
23
Butyric Acid Experimental Phase 3 107-92-6 264
24 Adjuvants, Immunologic Phase 2, Phase 3
25 Anti-Inflammatory Agents Phase 3,Phase 2
26 Cortisol succinate Phase 3
27 Hydrocortisone 17-butyrate 21-propionate Phase 3
28 Hydrocortisone acetate Phase 3
29 Hydrocortisone-17-butyrate Phase 3
30
Interferon alfacon-1 Approved Phase 1, Phase 2 118390-30-0 9554198
31
Thymalfasin Approved, Investigational Phase 2 62304-98-7
32 interferons Phase 1, Phase 2
33 Pharmaceutical Solutions Phase 2
34 Agglutinins Phase 1, Phase 2
35 Anti-Bacterial Agents Phase 2
36 Antibiotics, Antitubercular Phase 2
37 Anticholesteremic Agents Phase 2
38 Antimetabolites Phase 2
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
40 Hypolipidemic Agents Phase 2
41 Lipid Regulating Agents Phase 2
42 Antibodies, Monoclonal Phase 2
43 Calcium, Dietary Phase 2
44 Rosuvastatin Calcium Phase 2 147098-20-2
45
Aluminum sulfate Approved Phase 1 10043-01-3
46 Interleukin-2
47 Aluminum phosphate
48 Antacids
49 Anti-Ulcer Agents
50 Gastrointestinal Agents

Interventional clinical trials:

(show top 50) (show all 166)

id Name Status NCT ID Phase Drugs
1 The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A Unknown status NCT01127282 Phase 4 Vitamin (vitamin A 15 mg,C 500 mg, E 400IU);Placebo (digestive tablet)
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
4 Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects Completed NCT01069367 Phase 4
5 H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients Completed NCT01111162 Phase 4
6 A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines Completed NCT01004653 Phase 4
7 Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults Completed NCT01032980 Phase 4
8 Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults Completed NCT01008137 Phase 4
9 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV Completed NCT01002040 Phase 4
10 Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients Completed NCT01022905 Phase 4
11 Safety of H1N1 Influenza Vaccination in Pregnant Women Completed NCT01842997 Phase 4
12 Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children Completed NCT01000831 Phase 4
13 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults Completed NCT01001026 Phase 4
14 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine Completed NCT01000584 Phase 4
15 Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects Completed NCT01079273 Phase 4
16 Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine Completed NCT01023776 Phase 4
17 Vaccination Against Influenza in Autoimmune Diseases Completed NCT01065285 Phase 4
18 Phase IV Clinical Trial of an Influenza Split Vaccine Anflu Completed NCT00556062 Phase 4
19 A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults Completed NCT00945893 Phase 4
20 A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age Completed NCT00946101 Phase 4
21 Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older Completed NCT01114620 Phase 4
22 A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season Completed NCT01457027 Phase 4
23 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
24 Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children Withdrawn NCT01097941 Phase 4
25 Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine Unknown status NCT01582633 Phase 2, Phase 3
26 Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month Unknown status NCT01040078 Phase 3
27 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects Completed NCT01000207 Phase 2, Phase 3
28 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years) Completed NCT00972816 Phase 2, Phase 3
29 Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India Completed NCT01053143 Phase 3
30 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years) Completed NCT00973700 Phase 3
31 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults Completed NCT00973349 Phase 2, Phase 3
32 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects Completed NCT00996138 Phase 2, Phase 3
33 Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors Completed NCT01031719 Phase 3
34 Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection Completed NCT01032408 Phase 3
35 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Completed NCT00970177 Phase 3
36 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Completed NCT00971906 Phase 3
37 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age Completed NCT00971100 Phase 3
38 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age Completed NCT00971542 Phase 3
39 Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults Completed NCT00989287 Phase 3
40 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes Completed NCT00992511 Phase 3
41 Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza? Completed NCT01001325 Phase 3
42 Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus Completed NCT01032395 Phase 3
43 Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months Completed NCT00996307 Phase 2, Phase 3
44 Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age Completed NCT01051661 Phase 3
45 A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine Completed NCT01201902 Phase 3
46 Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older Completed NCT00979602 Phase 3
47 A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection Terminated NCT00979667 Phase 3 Oseltamivir;Zanamivir;Placebo of Oseltamivir
48 Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu Terminated NCT01014364 Phase 3 hydrocortisone;isotonic saline
49 Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults Unknown status NCT01155037 Phase 2
50 The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine Unknown status NCT01336166 Phase 2

Search NIH Clinical Center for Swine Influenza

Genetic Tests for Swine Influenza

Anatomical Context for Swine Influenza

MalaCards organs/tissues related to Swine Influenza:

39
Testes, Lung, Heart, T Cells, Neutrophil, Brain

Publications for Swine Influenza

Articles related to Swine Influenza:

(show top 50) (show all 596)
id Title Authors Year
1
Harnessing Local Immunity for an Effective Universal Swine Influenza Vaccine. ( 28475122 )
2017
2
Genetic analysis of human and swine influenza A viruses isolated in Northern Italy during 2010-2015. ( 28791803 )
2017
3
Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice. ( 28941982 )
2017
4
Characterization of Monoclonal Antibodies against HA Protein of H1N1 Swine Influenza Virus and Protective Efficacy against H1 Viruses in Mice. ( 28786930 )
2017
5
Genome Sequence of an Unusual Reassortant H1N1 Swine Influenza Virus Isolated from a Pig in Russia, 2016. ( 28883131 )
2017
6
Feral Swine in the United States Have Been Exposed to both Avian and Swine Influenza A Viruses. ( 28733290 )
2017
7
Influence of microclimate conditions on the cumulative exposure of nursery pigs to swine influenza A viruses. ( 28940764 )
2017
8
Kaempferol ameliorates H9N2 swine influenza virus-induced acute lung injury by inactivation of TLR4/MyD88-mediated NF-I_B and MAPK signaling pathways. ( 28262619 )
2017
9
Letter to the editor: Just a coincidence? Two severe human cases due to swine influenza (SIV) A(H1N1)v in Europe, October 2016. ( 28300531 )
2017
10
Pathogenicity and transmission of a swine influenza A(H6N6) virus. ( 28400591 )
2017
11
Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes. ( 27995691 )
2017
12
Protection of human influenza vaccines against a reassortant swine influenza virus of pandemic H1N1 origin using a pig model. ( 28267619 )
2017
13
A Single-Amino-Acid Substitution at Position 225 in HA Alters the Transmissibility of Eurasian Avian-like H1N1 Swine Influenza Virus in Guinea Pigs. ( 28814518 )
2017
14
Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. ( 28057521 )
2017
15
Kinetics of single and dual infection of pigs with swine influenza virus and Actinobacillus pleuropneumoniae. ( 28284596 )
2017
16
Comparison of mono- and co-infection by swine influenza A viruses and porcine respiratory coronavirus in porcine precision-cut lung slices. ( 28779714 )
2017
17
Authors' reply: Two severe human cases due to swine influenza A (H1N1)v in October 2016 in Europe were chronologic coincident yet distinct events. ( 28300530 )
2017
18
PA-X protein decreases replication and pathogenicity of swine influenza virus in cultured cells and mouse models. ( 28622865 )
2017
19
Pathogenicity and transmission of triple reassortant H3N2 swine influenza A viruses is attenuated following Turkey embryo propagation. ( 28284612 )
2017
20
Estimation of the transmission parameters for swine influenza and porcine reproductive and respiratory syndrome viruses in pigs from weaning to slaughter under natural conditions. ( 28237230 )
2017
21
Epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor and effectively alleviates acute lung injury induced by H9N2 swine influenza virus. ( 28858723 )
2017
22
Pathogenic characteristics of a novel triple-reasserted H1N2 swine influenza virus. ( 27230301 )
2016
23
Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs. ( 27016770 )
2016
24
Determination of current reference viruses for serological study of swine influenza viruses after the introduction of pandemic 2009 H1N1 (pdmH1N1) in Thailand. ( 27355862 )
2016
25
Distinct immune responses and virus shedding in pigs following aerosol, intra-nasal and contact infection with pandemic swine influenza A virus, A(H1N1)09. ( 27765064 )
2016
26
Fatal swine influenza A H1N1 and Mycoplasma pneumoniae coinfection in a child. ( 28393730 )
2016
27
Maternally Derived Immunity Extends Swine Influenza A Virus Persistence within Farrow-to-Finish Pig Farms: Insights from a Stochastic Event-Driven Metapopulation Model. ( 27662592 )
2016
28
Rapid detection and subtyping of European swine influenza viruses in porcine clinical samples by haemagglutinin- and neuraminidase-specific tetra- and triplex real-time RT-PCRs. ( 27397600 )
2016
29
In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model. ( 27411061 )
2016
30
A Phylogeny-Based Global Nomenclature System and Automated Annotation Tool for H1 Hemagglutinin Genes from Swine Influenza A Viruses. ( 27981236 )
2016
31
Mycoplasma hyopneumoniae does not affect the interferon-related anti-viral response but predisposes the pig to a higher inflammation following swine influenza virus infection. ( 27498789 )
2016
32
Protective efficacy of an inactivated Eurasian avian-like H1N1 swine influenza vaccine against homologous H1N1 and heterologous H1N1 and H1N2 viruses in mice. ( 27321744 )
2016
33
Novel triple-reassortant H1N1 swine influenza viruses in pigs in Tianjin, Northern China. ( 26790939 )
2016
34
Prevalence, genetics, and transmissibility in ferrets of Eurasian avian-like H1N1 swine influenza viruses. ( 26711995 )
2016
35
Spillback transmission of European H1N1 avian-like swine influenza viruses to turkeys: A strain-dependent possibility? ( 27016764 )
2016
36
An Underestimated Co-infection: Swine Influenza and Pneumonia Due to Legionella pneumophila. ( 27650238 )
2016
37
Maternally-derived antibodies do not prevent transmission of swine influenza A virus between pigs. ( 27530456 )
2016
38
The Molecular Determinants of Antibody Recognition and Antigenic Drift in the H3 Hemagglutinin of Swine Influenza A Virus. ( 27384658 )
2016
39
Effects of PB1-F2 on the pathogenicity of H1N1 swine influenza virus in mice and pigs. ( 28008819 )
2016
40
Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China. ( 27828989 )
2016
41
The global antigenic diversity of swine influenza A viruses. ( 27113719 )
2016
42
Severe acute respiratory infection caused by swine influenza virus in a child necessitating extracorporeal membrane oxygenation (ECMO), the Netherlands, October 2016. ( 27934581 )
2016
43
H1N1 Swine Influenza Viruses Differ from Avian Precursors by a Higher pH Optimum of Membrane Fusion. ( 26608319 )
2016
44
Virologic differences do not fully explain the diversification of swine influenza viruses in the United States. ( 27581984 )
2016
45
A cross-sectional study of swine influenza in intensive and extensive farms in the northeastern region of the state of SALo Paulo, Brazil. ( 27637594 )
2016
46
Truncation of C-terminal 20 amino acids in PA-X contributes to adaptation of swine influenza virus in pigs. ( 26912401 )
2016
47
Knowledge and Awareness Regarding Swine-Influenza A (H1N1) Virus Infection among Dental Professionals in India - A Systematic Review. ( 27790597 )
2016
48
Vaccination-challenge studies with a Port Chalmers/73 (H3N2)-based swine influenza virus vaccine: Reflections on vaccine strain updates and on the vaccine potency test. ( 25804707 )
2015
49
Acute appendicitis in a child with swine influenza (H1N1). ( 25814027 )
2015
50
Ceftiofur hydrochloride affects the humoral and cellular immune response in pigs after vaccination against swine influenza and pseudorabies. ( 26493336 )
2015

Variations for Swine Influenza

Expression for Swine Influenza

Search GEO for disease gene expression data for Swine Influenza.

Pathways for Swine Influenza

GO Terms for Swine Influenza

Biological processes related to Swine Influenza according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of insulin secretion GO:0050796 8.96 SLC8B1 TNF
2 animal organ morphogenesis GO:0009887 8.8 FGD1 TNF TREH

Molecular functions related to Swine Influenza according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hydrolase activity, acting on glycosyl bonds GO:0016798 8.62 NEU1 TREH

Sources for Swine Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....